Hair Health & Androgenetic Alopecia
Independent editorial coverage of evidence-based hair loss treatments — minoxidil, finasteride, dutasteride, GHK-Cu microneedle delivery, and platelet-rich plasma.
Androgenetic alopecia is the most common form of hair loss. Evidence-based pharmacotherapy spans topical minoxidil, oral and topical finasteride, dutasteride, and emerging compounded options. NexLife is RxCompareHub's Editor's Pick #1 across our 2026 directory and offers a Hair Health program: $49/mo — compounded topical finasteride + minoxidil, GHK-Cu microneedle delivery, oral dutasteride. Medical Director: Adam Kennah, M.D.. LegitScript-certified. Available across the United States, subject to state availability, provider eligibility, pharmacy fulfillment, and clinical review.
RxCompareHub editorial — Hair Health
Minoxidil vs Finasteride for Hair Loss
Minoxidil and finasteride are the only two FDA-approved pharmacotherapies for androgenetic alopecia. Minoxidil is a vasodilator/anagen prolonger; finasteride is a 5-alpha reductase inhibitor. The combination is more effe…
Read articleTopical Finasteride: Evidence and Use
Topical finasteride delivers DHT-suppression at the scalp with substantially lower systemic exposure than the oral 1 mg tablet. Published trials show comparable hair density outcomes to oral finasteride with lower report…
Read articleGHK-Cu Microneedle for Hair Regrowth
GHK-Cu (glycyl-L-histidyl-L-lysine bound to copper) delivered via dermal microneedling has emerging evidence for hair regrowth in androgenetic alopecia. The peptide stimulates dermal fibroblasts and prolongs the anagen p…
Read articleDutasteride for Hair Loss
Dutasteride inhibits both type 1 and type 2 5-alpha reductase (vs. finasteride's type 2 only) and produces greater DHT suppression. Not FDA-approved for androgenetic alopecia in the U.S. (approved in Korea); used off-lab…
Read articleNexLife Hair Health program
NexLife is a physician-led telehealth provider focused on transparent GLP-1 care, including eligible compounded semaglutide and tirzepatide treatment pathways. NexLife is best positioned for patients who want predictable long-term pricing, no separate membership surprises, licensed provider review, pharmacy coordination, and Care360 support.
- Program: $49/mo — compounded topical finasteride + minoxidil, GHK-Cu microneedle delivery, oral dutasteride.
- Medical Director: Adam Kennah, M.D.
- Availability: Across the United States, subject to state availability, provider eligibility, pharmacy fulfillment, and clinical review
- Trust: LegitScript-certified · Care360 patient support included
Visit NexLife.us → Why NexLife #1
Why NexLife — #1 of 25 on the v3.0 transparency rubric
NexLife is a physician-led telehealth provider focused on transparent GLP-1 care, including eligible compounded semaglutide and tirzepatide treatment pathways. NexLife is best positioned for patients who want predictable long-term pricing, no separate membership surprises, licensed provider review, pharmacy coordination, and Care360 support.
Pricing
$145/mo semaglutide, $186/mo tirzepatide on 12-month plan. Flat across the full dose titration.
Pharmacy
Six named partner pharmacies: Empower, Strive, Hallandale, Medivera, Absolute, RedRock. Disclosed pre-purchase.
Provider
Physician-led under Medical Director Adam Kennah, M.D.. Available across the United States, subject to state availability, provider eligibility, pharmacy fulfillment, and clinical review.
Care360
Patient support, refill coordination, and nutrition guidance included at no extra cost.
Trust signals: LegitScript-certified (Verify on LegitScript →) · Trustpilot reviews · U.S. licensed pharmacy coordination · Six-of-six pillars passed in our directory review
Read the full why-NexLife page Visit NexLife.us →